Bulletin
Investor Alert

May 18, 2020, 10:40 a.m. EDT

Upward Moving Stocks Of The Week: $SRNE $NVAX $CBAY

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Sorrento Therapeutics Inc. (SRNE)
  • X
    Novavax Inc. (NVAX)
  • X
    CymaBay Therapeutics Inc. (CBAY)

or Cancel Already have a watchlist? Log In

May 18, 2020 (The Market Signal via Comtex) -- Sector Reports was created as a platform to help investors find the best free Stock Reports on stocks they own. If you are a shareholder or looking for stocks to buy /zigman2/quotes/205669265/composite SRNE +4.00% , /zigman2/quotes/202614340/composite NVAX -2.01% or /zigman2/quotes/201917619/composite CBAY +3.89% then we strongly urge you to join our community by signing up with the link below and getting a completely free research report on each company today.

http://www.sectorreports.com.au/lP/?symbol=FREE-REPORT

(Click link above or copy, paste and hit enter in your browser for your report)

Sorrento Joins Hands With Celularity To Fight Against COVID-19

https://www.sectorreports.com.au/landing-page/?symbol=SRNE

(Click link above or copy, paste and hit enter in your browser for your report)

Sorrento Therapeutics Inc /zigman2/quotes/205669265/composite SRNE +4.00% was up 160.00% over the last one week. Last month, the company announced initiating the next phase of joining hands with Celularity, Inc, which is a Warren, New Jersey- based cell Therapeutics Company. Adding Celularity, Inc will provide a competitive edge to Sorrento in the fight against COVID-19.

On April 2, Celularity declared getting U.S. Food and Drug Administration (FDA) nod for proprietary CYNK-001, its Investigational New Drug (IND) application to be used in COVID-19 patients.

Celularity also declared commencing Phase I/II clinical study, where 86 patients infected with COVID-19 shall be included. In the partnership, Sorrento will provide manufacturing support to the company.

Novavax Announces Q1 2020 Report; Analysts Lift Revenue Estimates

https://www.sectorreports.com.au/landing-page/?symbol=NVAX

(Click link above or copy, paste and hit enter in your browser for your report)

Novavax, Inc. /zigman2/quotes/202614340/composite NVAX -2.01% was up 88.27% in the previous one week. The company reported its first quarter earnings for the year. The revenue was $3.4 million, while the statutory loss per share amounted $0.58, lower than the analysts estimate.

Company presented the results by aggregating latest statutory forecasts. On the basis of latest report presented by Novavax, five different analysts pegged company's revenues for the year at $10.9 million, reflecting 40% sales reduction. Interestingly, prior to Novavax's announcement, analysts had pegged revenues for the year at $7.17 million.

Losses are forecasted to fall 67% at $1.28 million. The sizeable change in analysts forecast of revenues and reducing losses is an indication that investors can rest assured now.

CymaBay Reviewers Have Positive Conclusion For Seladelpar's Use

https://www.sectorreports.com.au/landing-page/?symbol=CBAY

(Click link above or copy, paste and hit enter in your browser for your report)

/zigman2/quotes/205669265/composite
US : U.S.: Nasdaq
$ 8.06
+0.31 +4.00%
Volume: 30.68M
July 10, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.63 billion
Rev. per Employee
$55,479
loading...
/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 94.36
-1.94 -2.01%
Volume: 3.07M
July 10, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$5.47 billion
Rev. per Employee
$90,470
loading...
/zigman2/quotes/201917619/composite
US : U.S.: Nasdaq
$ 3.47
+0.13 +3.89%
Volume: 1.30M
July 10, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$239.02 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/205669265/composite
US : U.S.: Nasdaq
$ 8.06
+0.31 +4.00%
Volume: 30.68M
July 10, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.63 billion
Rev. per Employee
$55,479
loading...
/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 94.36
-1.94 -2.01%
Volume: 3.07M
July 10, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$5.47 billion
Rev. per Employee
$90,470
loading...
1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.